New inhaler combo could slow lung decline in smokers at risk of COPD
NCT ID NCT07595796
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) in 23 smokers aged 40-75 with PRISm, a lung condition that often progresses to COPD. Participants will use the inhaler twice daily for 12 weeks. The goal is to see if it improves lung function, symptoms, and quality of life, and to check for side effects. This is an early, small trial with no placebo group, so results will be preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Budesonide/glycopyrronium/formoterol inhalation aerosol (a triple-combination inhaler)
- What this could lead to
- If this trial works, it could point toward an effective treatment for PRISm, potentially delaying or preventing progression to COPD.
- What could go wrong
- This is a very small, early-phase trial with only 23 participants and no comparison group, so results may not be reliable or generalizable. The treatment may not work or could cause side effects like cardiovascular events.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRESERVED RATIO IMPAIRED SPIROMETRY (PRISM) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.